Moderna (MRNA)

Moderna's stock price has recently been fluctuating around lows. As of May 20, it was near $46.99, still below the 20-day (49.36) and 50-day (51.07) simple moving averages, indicating short- to medium-term bearish momentum, but well above the long-term 200-day (36.75) moving average. It is worth noting that the stock price has rebounded approximately 50% from the late 2025 cyclical low, and technically, it appears to be forming a long-term "cup and handle" pattern.
The company's Q1 2026 earnings per share was -$3.40, below market expectations; however, the company achieved a 260.2% year-over-year revenue growth. Market focus is gradually shifting toward the long-term prospects of the company's mRNA pipeline, including potential new project catalysts, which have somewhat boosted investor sentiment. On the insider front, the company's president exercised options and sold 53,336 shares at $48.40 on May 15, reflecting a somewhat cautious attitude from management regarding the current stock price.
Technical indicators
Weak signals persist — the daily chart remains under pressure from multiple short- and medium-term moving averages. However, some oversold signals suggest a higher probability of a short-term rebound to the 44.89–48.39 range. To confirm a positive medium-term trend, the stock price needs to effectively recover key moving averages and break through the resistance zone around $56–$60.

Moderna's mRNA pipeline outlook is positive, and oversold technical signals indicate a high probability of a rebound. Earnings fell short of expectations, management insiders reduced holdings, and short- to medium-term moving averages are under pressure.